What is HUM stock price target for 2026?

WallStSmart's 12-month price target for Humana Inc is $171.20, representing 29.6% downside from the current price of $243.12.

What is HUM stock forecast?

Humana Inc forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is HUM undervalued based on price targets?

Our DCF intrinsic value for Humana Inc is $1,081.11, against a current price of $243.12. The margin of safety is 79.89%.

HUM

Humana Inc

NYSE: HUM · HEALTHCARE · HEALTHCARE PLANS

$243.12

+5.83% today

Updated 2026-04-29

Market cap

$29.19B

P/E ratio

25.97

P/S ratio

0.23x

EPS (TTM)

$9.36

Dividend yield

—

52W range

$162 – $312

Volume

1.8M

Market cap

$29.19B

P/E ratio

25.97

P/S ratio

0.23x

EPS (TTM)

$9.36

Dividend yield

—

52W range

$162 – $312

Volume

1.8M

Humana Inc (HUM) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$243.12

Consensus

$238.65

-1.84%

2030 Target

$882.10

+262.82%

DCF

$1,081.11

+79.89% MoS

Current price

$243.12

Analyst consensus

$238.65

-1.84%

2030 Target

$882.10

+262.82%

Intrinsic (DCF)

$1,081.11

+79.89% MoS

20 analysts:

3 Buy13 Hold2 Sell

Management guidance

No specific CEO revenue targets were disclosed in the available data. Management has focused on operational initiatives (CenterWell expansion, value-based care partnerships, data interoperability) rather than issuing explicit forward revenue guidance. The company has announced a 2.48% Medicare Advantage rate increase for 2027, which provides revenue tailwind but management has not quantified total revenue targets.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$1,394.95

$211.5B Rev × 0.8x P/S

Base case (2030)

$882.10

$211.5B Rev × 0.5x P/S

Bear case (2030)

$533.36

$211.5B Rev × 0.3x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$106.4B	$117.8B	$129.7B	$163.6B	$178.9B	$194.8B	$197.8B	$211.5B
Revenue growth	—	10.7%	10.1%	26.1%	9.4%	8.8%	6.9%	6.9%
EPS	$25.99	$16.19	$14.48	$9.33	$13.80	$16.50	$17.85	$19.20
P/S ratio	—	—	—	0.5x	0.5x	0.5x	0.5x	0.5x
Implied price	—	—	—	$694.35	$757.48	$820.60	$820.56	$882.10

Catalysts & risks

Growth catalysts

+ 2.48% Medicare Advantage rate increase finalized for 2027 providing immediate revenue lift

+ CenterWell expansion and value-based care partnerships driving higher-margin revenue growth

+ Data interoperability initiatives (b.well partnership) improving member retention and lifetime value

+ Resolution of 2025 data breach and potential negative impact on member retention abating

Key risks

- Data breach (Sept 2025) exposing SSNs and medical claims creating member attrition risk and regulatory scrutiny

- Regulatory pressure on Medicare Advantage rates and antitrust investigations into PBM practices

- Medical cost inflation outpacing premium growth, compressing already-thin 0.9% profit margins

- Rising competition from UnitedHealth (UNH) with superior integrated platform; CVS Health and Cigna scale advantages

Methodology

Humana Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 20 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 21, 2026.